Goldman Sachs analyst Ziyi Chen upgraded Luye Pharma (LYPHF) to Neutral from Sell with a HK$3.13 price target The firm believes the downside risks have been largely reflected in the stock’s valuation.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LYPHF:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue